ENTITY
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
Protagonist, profit, Takeda, Quarter, Report (document), earnings, Takeda’s
Teva to offload API business as it concentrates on lead drug products
business career, Teva, API, lead drug products, offload, products
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Nordisk, Ozempic, Constant – dosing instruction fragment, exchange rate
GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun
Arexvy, Respiratory syncytial virus, battle, begun
FDA rejects Defender’s motion sickness treatment
United States Food and Drug Administration, Safety, Effectiveness
Promising Vertex Pain Med Points to New Era for Analgesics
historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects
Gilead Expands Arcus Collaboration with $320M Equity Investment
Investments, Arcus, Gilead, Combined, Phase 3 Clinical Trials
Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx
sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market
Bristol Myers’ Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data
Bristol, Myers, Opdivo, post-kidney cancer surgery test, Continuance of life
AbbVie pours $223M into building out its biologics capacity in Singapore
Biological Factors, expansion, AbbVie, Capacity, Investments, Manufacture, Singapore